<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729751</url>
  </required_header>
  <id_info>
    <org_study_id>MRX-801</org_study_id>
    <secondary_id>2020-004628-40</secondary_id>
    <nct_id>NCT04729751</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).</brief_title>
  <acronym>RISE</acronym>
  <official_title>Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess whether the investigational drug maralixibat, is safe and&#xD;
      well tolerated in children &lt;12 months of age with Alagille Syndrome [ALGS] or Progressive&#xD;
      Familial Intrahepatic Cholestasis [PFIC].&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label study where all participants will receive maralixibat treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group with 2 cohorts - ≥ 6 participants each from ALGS and PFIC.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events [TEAEs]</measure>
    <time_frame>From Baseline through to Week 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum bile acid (sBA) levels</measure>
    <time_frame>From Baseline through to Week 13</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Progressive Familial Intrahepatic Cholestasis</condition>
  <condition>Alagille Syndrome</condition>
  <condition>Cholestatic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Maralixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive up to 600 μg/kg twice daily (PFIC) or up to 400 μg/kg once daily (ALGS) over 13 weeks in the core study and for the duration of the Long Term Extension (LTE) where applicable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maralixibat</intervention_name>
    <description>Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)&#xD;
400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base&#xD;
600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base</description>
    <arm_group_label>Maralixibat</arm_group_label>
    <other_name>Formerly LUM001 and SHP625</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body weight of ≥2.5 kg&#xD;
&#xD;
          2. &lt;12 months of age at the baseline visit&#xD;
&#xD;
          3. Gestational age ≥36 weeks at birth. Those with gestational age &lt;36 weeks at birth with&#xD;
             no present clinical or developmental preterm complications that could impact&#xD;
             participation in the study may be included&#xD;
&#xD;
          4. Diagnosis of PFIC or ALGS&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Predicted complete absence of bile salt excretion pump (BSEP) function&#xD;
&#xD;
          2. History of surgical disruption of the enterohepatic circulation&#xD;
&#xD;
          3. History of liver transplant or imminent need for liver transplant&#xD;
&#xD;
          4. Decompensated cirrhosis&#xD;
&#xD;
          5. Presence of any other disease or condition known to interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of drugs, including bile salt metabolism in the&#xD;
             intestine (e.g., inflammatory bowel disease), per investigator discretion&#xD;
&#xD;
          6. Presence of other significant liver disease or any other conditions or abnormalities&#xD;
             which, in the opinion of the investigator or medical monitor, may compromise the&#xD;
             safety of the participant or interfere with the participant's participation in or&#xD;
             completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>364 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Mirum</last_name>
    <phone>+16506674085</phone>
    <email>clinicaltrials@mirumpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mirum Medical Information</last_name>
    <email>medinfo@mirumpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children Hospital LA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>skoch@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Chuan-Hao Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Carissa.Vinovskis@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Udeme Ekong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>richeys@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Simon Horslen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Melissa.young@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Evelyn Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>etienne.sokal@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Etienne Sokal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hubert.lesur-ext@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Gonzales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>florence.lacaille@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Lacaille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik-Centrum Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>i.jankowska@ipczd.pl</email>
    </contact>
    <investigator>
      <last_name>Irena Jankowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>richard.j.thompson@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/progressive-familial-intrahepatic-cholestasis</url>
    <description>Genetics Home Reference - PFIC</description>
  </link>
  <link>
    <url>https://mirumpharma.com</url>
    <description>Mirum Pharmaceuticals homepage</description>
  </link>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/alagille-syndrome</url>
    <description>Genetics Home Reference - ALGS</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>US FDA Resources</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PFIC</keyword>
  <keyword>ALGS</keyword>
  <keyword>Maralixibat</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
    <mesh_term>Alagille Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

